80165-23-7

Basic information

• Product Name: L-GlutaMic acid, 1-(1,1-diMethylethyl) 5-(phenylMethyl) ester
• Synonyms: L-GlutaMic acid, 1-(1,1-diMethylethyl) 5-(phenylMethyl) ester
• CAS NO: 80165-23-7
• Molecular Formula: C₁₆H₂₃NO₄
• Molecular Weight: 293.35812
• Mol File: 80165-23-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: L-GlutaMic acid, 1-(1,1-diMethylethyl) 5-(phenylMethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-GlutaMic acid, 1-(1,1-diMethylethyl) 5-(phenylMethyl) ester(80165-23-7)
• EPA Substance Registry System: L-GlutaMic acid, 1-(1,1-diMethylethyl) 5-(phenylMethyl) ester(80165-23-7)

Safety Data

• Hazardous Substances Data: 80165-23-7(Hazardous Substances Data)

Usage

General Description

L-Glutamic acid, 1-(1,1-dimethylethyl) 5-(phenylmethyl) ester is a chemical compound that is derived from glutamic acid and contains a tert-butyl group and a phenylmethyl ester group. It is commonly used as a flavor enhancer in food products due to its ability to enhance the savory taste known as umami. L-Glutamic acid, 1-(1,1-dimethylethyl) 5-(phenylmethyl) ester has been shown to have antioxidant properties, as well as potential neuroprotective effects. It is also used in the pharmaceutical industry for its potential therapeutic benefits, such as in the treatment of neurodegenerative disorders. However, like any chemical compound, careful consideration should be taken when using it to avoid potential side effects or allergic reactions.

Upstream product

• 28812-54-6 N-tert-butoxyxarbonyl-L-glutamic acid γ-benzyl α-tert-butyl diester 
• 1676-73-9 glutamic acid γ-benzyl ester 
• 115-11-7 isobutene 
• 540-88-5 acetic acid tert-butyl ester 
• 1676-73-9 L-glutamic acid γ-benzyl ester 
• 157108-58-2 (S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanedioic acid 5-benzyl ester 1-tert-butyl ester 
• 104-15-4 toluene-4-sulfonic acid 
• 2791-84-6 L-glutamic acid dibenzyl ester 4-toluenesulfonate 
• 56-86-0 L-glutamic acid 

Downstream Products

• 862778-54-9 2-bis(tert-butoxycarbonylmethyl)aminopentanedioic acid 5-benzyl ester 1-tert-butyl ester 
• 1192068-52-2 (S)-2-((S)-2-tert-butoxycarbonylaminopropionylamino)pentanedioic acid 5-benzyl ester 1-tert-butyl ester 
• 174267-74-4 C₄₄H₇₃N₃O₁₂ 
• 862778-55-0 2-(bis-tert-butoxycarbonylmethylamino)-pentanedioic acid 1-tert-butyl ester 
• 1026987-94-9 (S)-5-(tert-butoxy)-4-(3-((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl)ureido)-5-oxopentanoic acid 
• 223467-27-4 5-benzyl 1-tert-butyl N-(4-methylbenzoyl)-L-glutamate 
• 24277-39-2 α-tert-butyl N^α-(tert-butyloxycarbonyl)-L-glutamate 
• 91229-90-2 α-tert-butyl N^α-(tert-butyloxycarbonyl)-N^δ-tosyl-N^δ-(benzyloxy)-L-ornithine 
• 37513-14-7 N^δ-tosyl-N^δ-(benzyloxy)-L-ornithine 
• 91229-91-3 α-tert-butyl N^α-(tert-butyloxycarbonyl)-L-pyroglutamate 

Relevant articles and documents

Preparation and preliminary biological evaluation of 177Lu- labeled GluDTPA-cyclo(RGDfK) for integrin αvβ3 receptor-positive tumor targeting

Integrin αvβ3 is a receptor and is highly expressed on activated and proliferating endothelial cells during the growth and metastasis of solid tumors but not on resting endothelial cells and normal organs. Because RGD peptide binds to integrin αvβ 3 receptor, a variety of radiolabeled RGD peptides have been evaluated for non-invasive imaging of integrin αvβ 3-positive tumors. In an attempt to develop RGD-based radiopharmaceuticals, a novel GluDTPA-cyclo arginine-glycine-aspartic acid-d-phenylalanine-lysine (GluDTPA-cycloRGDfK) was simply synthesized and radiolabeled with 177Lu. Also, tumor targeting and retention of the radiolabeled complex were evaluated in U87MG glioma-bearing mice. The 177Lu-labeled GluDTPA-cyclo(RGDfK) was formulated with a high radiolabeling yield (>98%) under mild condition, and the radiochemical purity was sustained in both saline and serum for over 4days at 37°C. The radiolabeled compounds were rapidly cleared from the blood pool and non-target tissue. Tumor-to-blood ratio was 12.09 at 2h post injection and increased to 134.67 at 24h, while tumor to liver ratio was 2.01 at 24h similar to that of 2h. Though it is inappropriate for targeted therapy due to its low uptake in tumor (～ 1 %ID/g), the acceptable results on radiochemistry and biodistribution propose to take a further assessment for non-invasive imaging and detection of integrin αvβ3-positive tumors by applying diagnostic radionuclides.

Chemoselective deprotection of N-Boc group in amino acids and peptides by bismuth(III) trichloride

Selective deprotection of N-Boc group was achieved in excellent yields using bismuth(III) trichloride in a mixed solvent of acetonitrile and water (50:1, v/v) at 55°C. Acid-labile groups such as Pmc and tert-butyl ester were not affected and no alkylation of tryptophan, methionine, and cysteine residues was observed under the deprotection conditions.

Synthesis of N(α),N(δ)-protected N(δ)-hydroxy-L-ornithine from L-glutamic acid

-